These protective effects are accompanied by decreased expression of the pro-fibrotic biomarkers OPN, TIMP-1 and PAI-1, which have been shown to correlate with the severity of cardiovascular diseases and end-organ damage in clinical studies. The gene discussed is SPP1; the disease is cardiovascular disorder.